Skip to main content

Gevotroline









Gevotroline


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search

























































Gevotroline
Gevotroline.svg
Clinical data
Routes of
administration		 Oral
ATC code
  • None
Legal status
Legal status

  • In general: uncontrolled
Identifiers
CAS Number
  • 107266-06-8

PubChem CID
  • 60547
ChemSpider
  • 54579
UNII
  • 7SZ6A2091Q
ChEBI
  • CHEBI:142391
Chemical and physical data
Formula
C19H20FN3
Molar mass 309.38 g/mol
3D model (JSmol)
  • Interactive image

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]



See also[edit]



  • Atypical antipsychotic

  • Atiprosin

  • Azepindole



References[edit]





  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ abc Bristol, James A. (1990). Annual Reports in Medicinal Chemistry (Volume 25). Boston: Academic Press. ISBN 0-12-040525-3.


  3. ^ ab Stone, T. W.; Stone, Trevor (1996). CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press. ISBN 0-8493-7632-7.


  4. ^ Snyder SH, Largent BL (1989). "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences. 1 (1): 7–15. PMID 2577720.


  5. ^ Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C (January 1991). "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology. 30 (1): 79–87. doi:10.1016/0028-3908(91)90046-E. PMID 1675451.


  6. ^ Gudelsky GA, Nash JF (February 1992). "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology. 31 (2): 157–62. doi:10.1016/0028-3908(92)90026-L. PMID 1348112.














Retrieved from "https://en.wikipedia.org/w/index.php?title=Gevotroline&oldid=862767628"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.020","walltime":"1.201","ppvisitednodes":{"value":4746,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":435836,"limit":2097152},"templateargumentsize":{"value":110427,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":17965,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 677.518 1 -total"," 56.49% 382.750 1 Template:Drugbox"," 36.66% 248.397 1 Template:Infobox"," 30.57% 207.112 23 Template:Navbox"," 19.58% 132.691 1 Template:Reflist"," 18.75% 127.049 1 Template:Navboxes"," 11.41% 77.322 16 Template:Unbulleted_list"," 11.39% 77.185 3 Template:Cite_book"," 9.93% 67.271 1 Template:Serotonin_receptor_modulators"," 5.45% 36.916 3 Template:Cite_journal"]},"scribunto":{"limitreport-timeusage":{"value":"0.295","limit":"10.000"},"limitreport-memusage":{"value":4916186,"limit":52428800}},"cachereport":{"origin":"mw1240","timestamp":"20181216022722","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":101,"wgHostname":"mw1266"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more

13 indicted, 8 arrested in Calif. drug cartel investigation

Image
Fox News U.S. World Opinion Politics Entertainment Business Lifestyle TV Radio More Expand / Collapse search Login Watch TV ☰ Hot Topics U.S. Crime Military Education Terror Immigration Economy Personal Freedoms World U.N. Conflicts Terrorism Disasters Global Economy Environment Religion Scandals Opinion Politics Executive Senate House Judiciary Foreign policy Polls Elections Entertainment Celebrity News Movies TV News Music News Style News Entertainment Video Business Markets Politics Technology Features Business Leaders Lifestyle Food + Drink Cars + Trucks Travel + Outdoors House + Home Fitness + Well-being Style + Beauty Family Science Archaeology Air & Space Planet Earth Wild Nature Natural Science Dinosaurs Tech Security Innovation Drones Computers Video Games Military Tech Health Healthy Living Medical Research Mental Health Cancer Heart Health Children'
Read more